Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

Antimicrob Agents Chemother. 2005 Mar;49(3):884-8. doi: 10.1128/AAC.49.3.884-888.2005.

Abstract

Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the methicillin-resistance determinant of staphylococci, and is active against methicillin- and vancomycin-resistant Staphylococcus aureus. Ceftobiprole was compared to vancomycin in a rabbit model of methicillin-resistant S. aureus aortic valve endocarditis. Ceftobiprole and vancomycin were equally effective against endocarditis caused by methicillin-resistant S. aureus strain 76, whereas ceftobiprole was more effective than vancomycin against the vancomycin-intermediate S. aureus strain HIP5836. The activity of ceftobiprole against drug-resistant strains of S. aureus warrants its further clinical development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aortic Valve*
  • Cephalosporins / blood
  • Cephalosporins / therapeutic use*
  • Disease Models, Animal
  • Endocarditis, Bacterial / drug therapy*
  • Heart Valve Diseases / drug therapy*
  • Methicillin Resistance*
  • Microbial Sensitivity Tests
  • Rabbits
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects*
  • Vancomycin / blood
  • Vancomycin / therapeutic use*

Substances

  • Cephalosporins
  • ceftobiprole
  • Vancomycin